Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this clinical research study is to learn if BMS-582949 alone is an effective treatment for moderate to severe psoriasis. The safety of the drug and the effectiveness of each dose will also be studied.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A1 | Active Comparator | 10 mg |
|
| A2 | Active Comparator | 30 mg |
|
| A3 | Active Comparator | 100 mg |
|
| P1 | Placebo Comparator | 10 or 100 mg |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BMS-582949 | Drug | Tablets, Oral, Once daily, 12 weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| The primary endpoint is the proportion of subjects achieving an IGA score of clear or almost clear at Week 12 | at Week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of subjects achieving a PASI-50 | at Week 12 | |
| Proportion of subjects achieving a PASI-75 | at Week 12 | |
| Proportion of subjects achieving a PASI-90 |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution | Kogarah | New South Wales | 2217 | Australia | ||
| Local Institution |
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Tablets, Oral, Once daily, 12 weeks |
|
| at Week 12 |
| Greenslopes |
| Queensland |
| 4120 |
| Australia |
| Local Institution | North Adelaide | South Australia | 5006 | Australia |
| Local Institution | Carlton | Victoria | 3053 | Australia |
| Local Institution | Malvern | Victoria | 3144 | Australia |
| Local Institution | Calgary | Alberta | T3A 2N1 | Canada |
| Local Institution | Edmonton | Alberta | T5K 1X3 | Canada |
| Local Institution | Surrey | British Columbia | V3R 6A7 | Canada |
| Local Institution | Winnipeg | Manitoba | R2C 0N2 | Canada |
| Local Institution | St. John's | Newfoundland and Labrador | A1B 3E1 | Canada |
| Local Institution | Halifax | Nova Scotia | B3H 1Z4 | Canada |
| Local Institution | Oakville | Ontario | L6J 7W5 | Canada |
| Local Institution | Toronto | Ontario | M9W 4L6 | Canada |
| Local Institution | Waterloo | Ontario | N2J 1C4 | Canada |
| Local Institution | Montreal | Quebec | H3H 1V4 | Canada |
| Local Institution | Québec | Quebec | G1V 4X7 | Canada |
| Local Institution | Saint-Léonard | Quebec | H1S 3A9 | Canada |
| Local Institution | México | Aguascalientes | 20127 | Mexico |
| Local Institution | Zapopan | Jalisco | 45190 | Mexico |
| Local Institution | Df | Mexico City | 06780 | Mexico |
| Local Institution | Monterrey | Nuevo León | 64060 | Mexico |
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C552704 | 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo(1,2-f)(1,2,4)triazine-6-carboxamide |
Not provided
Not provided
Not provided